Treatment of Cardio Vascular Disease with low dose Rivaroxaban in Advanced Chronic Kidney Disease(TRACK) Read more about Treatment of Cardio Vascular Disease with low dose Rivaroxaban in Advanced Chronic Kidney Disease(TRACK)
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Read more about A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
" A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer" Read more about " A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer"
Multicenter, open-label, study to evaluate safety,tolerability, pharmacokinetics and, pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared with enalapril in pediatric patients from1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction) Read more about Multicenter, open-label, study to evaluate safety,tolerability, pharmacokinetics and, pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared with enalapril in pediatric patients from1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction)
Randomized, Open-Label, Clinical Trial for Evaluating the Prophylactic Use of Paracetamol for Fasting-induced Headache During the First Week of Ramadan Read more about Randomized, Open-Label, Clinical Trial for Evaluating the Prophylactic Use of Paracetamol for Fasting-induced Headache During the First Week of Ramadan
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis Read more about A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis
"A Phase III, Open-label, Randomized Study To Evaluate The Efficacy And Safety of Adjuvant Alectinib Versus Adjuvant Platinum-based Chemotherapy in Patients with Completely Resected Stage Ib (Tumors≥4 Cm) To Stage IIIa Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer " Read more about "A Phase III, Open-label, Randomized Study To Evaluate The Efficacy And Safety of Adjuvant Alectinib Versus Adjuvant Platinum-based Chemotherapy in Patients with Completely Resected Stage Ib (Tumors≥4 Cm) To Stage IIIa Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer "
"RAINBOW extension study: an extension study to evaluate the long term efficacy and safety of RAnibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity" Read more about "RAINBOW extension study: an extension study to evaluate the long term efficacy and safety of RAnibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity"
Stroke and High-risk TIAs Outcomes with Reduction of Treatment duration in Emergency Rooms. (SHORTER-Study). Read more about Stroke and High-risk TIAs Outcomes with Reduction of Treatment duration in Emergency Rooms. (SHORTER-Study).
A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active controlled, Parallel-group, Group-sequential, Adaptive, Event-driven Study to Compare Efficacy, Safety, and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension, Followed by an Open-label Treatment Period With Macitentan 75 mg. (UNISUS) Read more about A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active controlled, Parallel-group, Group-sequential, Adaptive, Event-driven Study to Compare Efficacy, Safety, and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension, Followed by an Open-label Treatment Period With Macitentan 75 mg. (UNISUS)
